汇丰银行-中国-医疗保健行业-中国医疗业：快速药物批准的好处-2018.11-79页.pdfVIP

EQUITY RESEARCH REPORT HEALTHCARE November 2018 By: Zhijie Zhao (S1700517110001) China Healthcare Fast forward – the benefits of quicker drug approvals China’s revamped drug approval system will lead to a surge in new product launches over 2018-20e The ability to make these new products a commercial success is the key differentiating factor for domestic pharma companies Initiate coverage of Livzon Pharma (A+H), Kelun Group and Huadong Medicine wit